THE ROLE OF ADAM9 IN COLORECTAL CANCER

The disintegrin and metalloproteinases (ADAMs) have long been associated with diseases such as cancer and arthritis. Among all the ADAMs, transmembrane ADAMs have been implicated in tumor progression and have emerged as new targets for cancer therapy. Previous research in our lab suggests that ADAM9, a transmembrane ADAMs that is highly expressed in many types of solid tumors, promotes colorectal cancer (CRC) progression. In this study, to better understand the role ADAM9 plays in colorectal cancer and provide guidance for targeting it as a novel approach of cancer treatment, we investigated the underlying mechanism of how ADAM9 regulates colorectal cancer using RNA-seq.

BIOGRAPHY

Congyu Lu is currently pursuing PhD in Bioinformatics Data Science. He is working as a research assistant in Dr. Shuo Wei’s lab in the department of Biological Science. He obtained a master’s degree in Biological Science at University in 2018. His current research is focused on investigating the role of ADAM9 in colorectal cancer using transcriptomics and proteomic analysis.